Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit-risk pr...
Source: Roche Media News - July 22, 2020 Category: Pharmaceuticals Source Type: news
Regeneron Funneled Kickbacks Through a Patient Charity, Federal Lawsuit Claims
The case is the latest inquiry into pharmaceutical companies ’ donations to patient assistance charities, which have been blamed for inflating the cost of drugs. (Source: NYT Health)
Source: NYT Health - June 24, 2020 Category: Consumer Health News Authors: Katie Thomas Tags: Regeneron Pharmaceuticals Inc Eylea (Drug) Drugs (Pharmaceuticals) Suits and Litigation (Civil) Bribery and Kickbacks Avastin (Drug) Lucentis (Drug) Nonprofit Organizations Chronic Disease Fund Genentech Inc your-feed-healthcare Source Type: news
Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to those recei...
Source: Roche Investor Update - May 27, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to those recei...
Source: Roche Media News - May 27, 2020 Category: Pharmaceuticals Source Type: news
Novel Anti-VEGF Delivery System Aims to Reshape AMD Treatment Novel Anti-VEGF Delivery System Aims to Reshape AMD Treatment
Early results highlight the promise of a permanent, refillable port implant, which allows sustained delivery of ranibizumab.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2020 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
Treat-and-Extend Approach With Ranibizumab Effective in AMD Treat-and-Extend Approach With Ranibizumab Effective in AMD
In patients with neovascular age-related macular disease, a treat-and-extend ranibizumab regimen is not inferior to injections given at fixed intervals, plus it ' s more convenient, according to a new clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab, Aflibercept Both Effective for Diabetic Macular Edema in Real World Ranibizumab, Aflibercept Both Effective for Diabetic Macular Edema in Real World
Both ranibizumab and aflibercept effectively treat diabetic macular edema (DME), one-year data from a registry study reveal.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy
At five years, intravitreous ranibizumab therapy for proliferative diabetic retinopathy (PDR) appears to be cost-effective relative to panretinal photocoagulation (PRP), but only in eyes with vision-impairing center-involved diabetic macular edema (CI-DME), according to new findings.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Novartis nabs FDA priority review for potential eye blockbuster
If approved this will have the drugmaker go head to head against Roche ’s Lucentis and Regeneron’s Eylea (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 16, 2019 Category: Pharmaceuticals Source Type: news
Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD
In patients with neovascular age-related macular degeneration (nAMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Panretinal photocoagulation may increase diabetic macular oedema risk
Research, published inThe American Journal of Clinical Nutrition, suggests that treatment of proliferative diabetic retinopathy with panretinal photocoagulation, rather than ranibizumab injections, may increase the risk of diabetic macular oedema.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 17, 2018 Category: Endocrinology Source Type: news
Genentech touts data for refillable eye implant in wet-AMD trial
Roche‘s (OTC:RHHBY) Genentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet age-related macular degeneration.
The company first reported top-line results from the Phase II Ladder study in July. The implant is intended to allow wet-AMD patients to go for months without needing to see an ophthalmologist for treatment; the current standard of care for wet-AMD patients involves monthly injections of therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech touts da...
Source: Mass Device - October 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news
Two Treatments, Similar Outcomes in Diabetic Retinopathy
(MedPage Today) -- Visual acuity similar at 5 years with ranibizumab, photocoagulation (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 16, 2018 Category: Endocrinology Source Type: news
Avastin/Lucentis/Eylea ruling good news for patients, says RPS
Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:“This is a landmark ruling and good news for patients (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 21, 2018 Category: Drugs & Pharmacology Source Type: news
